ULTIMOVACS ASA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.1 NOK | +2.45% |
|
-14.56% | -94.22% |
| Apr. 17 | Ultimovacs to Reduce 40% of Workforce Amid Operational Adjustments | MT |
| Apr. 17 | Transcript : Ultimovacs ASA - Special Call |
Presenter SpeechCarlos de Sousa (Executives)Good afternoon, good morning or good evening, depe...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Ultimovacs ASA is a Norway-based pharmaceutical company developing immunotherapies against cancer. Ultimovacsâ technology is based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital. Ultimovacs is advancing a broad clinical development program with clinical trials in Europe, Australia and the U.S. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
7.1
NOK
Average target price
6.5
NOK
Spread / Average Target
-8.45%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -94.22% | 22.12M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- ULTI Stock
- News Ultimovacs ASA
- Transcript : Ultimovacs ASA, Q2 2023 Earnings Call, Aug 22, 2023
